Cite
HARVARD Citation
Mourvillier, B. et al. (n.d.). LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia. Open forum infectious diseases. p. . [Online].